VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures.
Inhibition of vascular endothelial growth factor receptor (VEGFR) signalling, using either antibodies or small molecule inhibitors of the VEGFR kinase domain, has become a major area of research in oncology. The phthalazine PTK787/ZK222584, first published in the literature in 1998, is one of the most advanced VEGFR inhibitors in the clinic. This paper provides an update on the patenting activity related to the phthalazine class. In addition, newer kinase inhibitor pharmacophores derived from this class (e.g., anthranilamides) will be reviewed.
Bayer HealthCare, Pharmaceuticals Corporation, 400 Morgan Lane, West Haven, CT 06516, USA.
Jacques
J
Dumas
Julie A
JA
Dixon